Table 1. Patient and tumor characteristics (entire cohort).
| Patient or tumor characteristic | Adjuvant chemotherapy | No adjuvant therapy | P |
|---|---|---|---|
| N | 46 | 336 | |
| Median age (range), years | 60.2 (38.1–79.2) | 63.8 (30.0–86.3) | 0.047 |
| Sex | 0.535 | ||
| Male | 37 | 281 | |
| Female | 9 | 55 | |
| Ethnicity | 0.270 | ||
| Caucasian | 42 | 323 | |
| Other* | 4* | 13** | |
| Location | 0.583 | ||
| Upper 1/3 | 0 | 5 | |
| Middle 1/3 | 2 | 24 | |
| Lower 1/3 | 25 | 204 | |
| GE-junction | 19 | 103 | |
| Histology | 0.034 | ||
| Adenocarcinoma | 42 | 286 | |
| Squamous cell carcinoma | 2 | 47 | |
| Mixed | 2 | 3 | |
| ypT-classification | <0.001 | ||
| ypT0 | 6 | 167 | |
| ypT1 | 4 | 48 | |
| ypT2 | 14 | 52 | |
| ypT3 | 21 | 62 | |
| ypT4 | 1 | 7 | |
| ypN-classification | <0.001 | ||
| ypN0 | 10 | 256 | |
| ypN1 | 28 | 65 | |
| ypN2 | 5 | 12 | |
| ypN3 | 3 | 3 | |
| Neoadjuvant chemotherapy | 0.512 | ||
| Platinum + 5-FU/capecitabine | 41 | 283 | |
| Platinum + taxane | 5 | 53 | |
| Pathologic response | <0.001 | ||
| Complete | 3 | 154 | |
| Partial*** | 24 | 133 | |
| None | 19 | 49 | |
| Margin status | 0.007 | ||
| Negative | 39 | 322 | |
| Microscopic positive | 7 | 14 |
*, 3 Hispanic, 1 patient chose other as ethnicity; **, 6 Hispanic, 4 African American, 2 Asian, and 1 patient chose other as ethnicity; ***, partial was defined as a lower T-classification than seen on endoscopic ultrasound or node negativity with reported nodes positive on endoscopic ultrasound. Patient and tumor characteristics that were found to be significantly associated with adjuvant chemotherapy based on analysis with the entire cohort include age, histology, ypT and ypN classification, pathologic response, and margin status.